US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicines

84.90

0.0000

Volume:- -

Turnover:- -

Market Cap:6.79B

PE:-27.06

High:84.90

Open:84.90

Low:84.90

Close:84.90

Loading ...

Overview Company News Filings

TYK Medicines Announces Board and Committee Roles

Everest Medicines Expands Shareholder Base with Strategic Share Disposal

BeOne Medicines Says Data Shows High Overall Response of Sonrotoclax plus BRUKINSA in CLL, MCL Patients

MT Newswires Live

TYK Medicines, Inc. Seeks Approval for H Share Full Circulation

Everest Medicines Announces Virtual AGM with Key Resolutions

BeOne Medicines presents results from studies of BG-C9074, BG-68501 at ASCO

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

BeOne Medicines to present new data from Phase 3 SEQUOIA trial of BRUKINSA

BeOne Medicines Ltd. Strengthens Financial Oversight with Audit Committee Charter

BeOne Medicines Ltd. Files Post-Effective Amendment for Strategic Financial Flexibility

BeiGene Changes Name to BeOne Medicines, Completes Redomiciliation to Switzerland

MT Newswires Live

BeOne Medicines Ltd. Transitions to Swiss Corporation

TYK Medicines' VP Steps Down

MT Newswires Live

Press Release: Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

TYK Medicines Announces Management Restructuring

Viatris' HIV-1 Generic Medicine Gets Backing From European Medicines Agency

MT Newswires Live

Autolus Therapeutics' Leukemia Therapy Gets Backing From European Medicines Agency

MT Newswires Live

Press Release: Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

TYK Medicines Included in Hang Seng Biotech Index

MT Newswires Live

TYK Medicines Joins Hang Seng Biotech Index

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","market":"US","secType":"STK","nameCN":"Medicines","latestPrice":84.9,"timestamp":1578085200000,"preClose":84.9,"halted":3,"volume":0,"delay":0,"floatShares":74862655,"shares":79948329,"eps":-3.137449,"marketStatus":"Halted","change":0,"latestTime":"01-03 16:00:00 EST","open":84.9,"high":84.9,"low":84.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.137449,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":965707200000,"exchange":"NASDAQ","adjPreClose":84.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","floatShares":74862655,"roa":"-13.71%","roe":"553.30%","lyrEps":-1.673974,"shares":79948329,"dividePrice":0,"high":84.9,"amplitude":0,"preClose":84.9,"low":84.9,"week52Low":23.15,"pbRate":"178.02","week52High":84.98,"institutionHeld":1.2829,"latestPrice":84.9,"eps":-3.137449,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.137449,"open":84.9,"prevYearClose":84.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2543027085","title":"TYK Medicines Announces Board and Committee Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2543027085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543027085?lang=en_us&edition=fundamental","pubTime":"2025-06-13 17:12","pubTimestamp":1749805966,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. Class H ( ($HK:2410) ) has issued an update. TYK Medicines, Inc., a joint stock company incorporated in the People’s Republic o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-announces-board-and-committee-roles?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-announces-board-and-committee-roles?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2543752543","title":"Everest Medicines Expands Shareholder Base with Strategic Share Disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2543752543","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543752543?lang=en_us&edition=fundamental","pubTime":"2025-06-13 07:40","pubTimestamp":1749771647,"startTime":"0","endTime":"0","summary":"An announcement from Everest Medicines Ltd. ( ($HK:1952) ) is now available. Everest Medicines Ltd. announced that its controlling shareholder, CBC...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-expands-shareholder-base-with-strategic-share-disposal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-expands-shareholder-base-with-strategic-share-disposal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2542515460","title":"BeOne Medicines Says Data Shows High Overall Response of Sonrotoclax plus BRUKINSA in CLL, MCL Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2542515460","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542515460?lang=en_us&edition=fundamental","pubTime":"2025-06-12 19:10","pubTimestamp":1749726616,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) said Thursday that the phase 1 study of sonrotoclax plus BRUKINSA elicited a 96% overall response rate in relapsed/refractory chronic lymphocytic leukemia patients and a 79% over","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4526","ONC","MDCO","BK4139"],"gpt_icon":0},{"id":"2541085059","title":"TYK Medicines, Inc. Seeks Approval for H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2541085059","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541085059?lang=en_us&edition=fundamental","pubTime":"2025-06-06 20:37","pubTimestamp":1749213467,"startTime":"0","endTime":"0","summary":"The latest update is out from TYK Medicines, Inc. Class H ( ($HK:2410) ). TYK Medicines, Inc, a joint stock company incorporated in the People’s Re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-inc-seeks-approval-for-h-share-full-circulation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-inc-seeks-approval-for-h-share-full-circulation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2540917721","title":"Everest Medicines Announces Virtual AGM with Key Resolutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2540917721","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540917721?lang=en_us&edition=fundamental","pubTime":"2025-06-03 17:10","pubTimestamp":1748941816,"startTime":"0","endTime":"0","summary":"An update from Everest Medicines Ltd. ( ($HK:1952) ) is now available. Everest Medicines Ltd. has announced that its Annual General Meeting (AGM) w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-announces-virtual-agm-with-key-resolutions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-announces-virtual-agm-with-key-resolutions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4229","BK4195","AGM","MDCO"],"gpt_icon":0},{"id":"2540676444","title":"BeOne Medicines presents results from studies of BG-C9074, BG-68501 at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2540676444","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540676444?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:15","pubTimestamp":1748859321,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology Annual Meet...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-presents-results-from-studies-of-bg-c9074-bg-68501-at-asco-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-presents-results-from-studies-of-bg-c9074-bg-68501-at-asco-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","LU0251142724.SGD","LU0385154629.USD","LU0742534661.SGD","BK4189","BK4588","BK4526","LU0471298694.HKD","LU0251131958.USD","BG","MDCO","BK4139","LU2360106947.USD","LU0471298777.SGD","LU0048573561.USD","BK4585","LU2211817866.USD"],"gpt_icon":0},{"id":"2540896749","title":"Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2540896749","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540896749?lang=en_us&edition=fundamental","pubTime":"2025-06-02 13:00","pubTimestamp":1748840400,"startTime":"0","endTime":"0","summary":"Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome. Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S   , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application  to the European Medicines Agency  for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome .EASE-1  was a randomized, double-blind Phase 3 trial that enrolled a total of 106 SBS patients with intestinal failure who were dependent on parenteral support for at least three days per week. Patients were evenly randomized to receive treatment with 10 mg glepaglutide administered either once or twice weekly, or placebo. The primary endpoint in the trial was the absolute change in weekly parenteral support volume from baseline at 24 weeks. At 24 weeks, glepaglutide administered tw","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-submits-marketing-authorization-050000407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","EMA","BK4215","MDCO","BK4172","BK4081","MAA","ZLDPY","BK4139","BK4588","SBS"],"gpt_icon":0},{"id":"2540308077","title":"BeOne Medicines to present new data from Phase 3 SEQUOIA trial of BRUKINSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2540308077","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540308077?lang=en_us&edition=fundamental","pubTime":"2025-06-02 03:50","pubTimestamp":1748807415,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA. These data will ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-to-present-new-data-from-phase-3-sequoia-trial-of-brukinsa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-to-present-new-data-from-phase-3-sequoia-trial-of-brukinsa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BMPRXQ63.HKD","BK4543","BK4588","MDCO","BK4526","BK4585","IE00BMPRXN33.USD","BK4609","LU0348723411.USD","BK4141","IE00BMPRXR70.SGD","ONC","BK4139"],"gpt_icon":0},{"id":"2538600426","title":"BeOne Medicines Ltd. Strengthens Financial Oversight with Audit Committee Charter","url":"https://stock-news.laohu8.com/highlight/detail?id=2538600426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538600426?lang=en_us&edition=fundamental","pubTime":"2025-05-28 17:09","pubTimestamp":1748423386,"startTime":"0","endTime":"0","summary":"The latest announcement is out from BeiGene Ltd ( ($HK:6160) ). BeOne Medicines Ltd. has outlined the purpose and structure of its Audit Committee,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-ltd-strengthens-financial-oversight-with-audit-committee-charter?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-ltd-strengthens-financial-oversight-with-audit-committee-charter?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4559","LU0289960550.SGD","LU1201861165.SGD","CHTR","LU0477156797.USD","LU0208291251.USD","LU0175139822.USD","LU0320765489.SGD","LU0211331839.USD","MDCO","BK4100","LU0130102774.USD","BK4585","LU1201861249.SGD","LU0130103400.USD","LU0477156953.USD","LU0070302665.USD","LU0130518102.USD","LU0648000940.SGD","LU0648001328.SGD","LU0980610538.SGD","BK4588","LU0130517989.USD"],"gpt_icon":0},{"id":"2538418591","title":"BeOne Medicines Ltd. Files Post-Effective Amendment for Strategic Financial Flexibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2538418591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538418591?lang=en_us&edition=fundamental","pubTime":"2025-05-28 07:39","pubTimestamp":1748389183,"startTime":"0","endTime":"0","summary":"BeiGene Ltd ( ($HK:6160) ) just unveiled an update. BeOne Medicines Ltd. has issued a post-effective amendment to its Form S-3 registration stateme...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-ltd-files-post-effective-amendment-for-strategic-financial-flexibility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-ltd-files-post-effective-amendment-for-strategic-financial-flexibility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4212","POST","MDCO"],"gpt_icon":0},{"id":"2538464563","title":"BeiGene Changes Name to BeOne Medicines, Completes Redomiciliation to Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2538464563","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538464563?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:34","pubTimestamp":1748352847,"startTime":"0","endTime":"0","summary":"BeiGene  said Tuesday it has changed its name to BeOne Medicines and completed its redomiciliation to Switzerland.The company said its shareholders approved the new name and redomiciliation to Switzerland from the Cayman Islands on April 28.The transition to its new name throughout its global operations will take effect in phases, the company added.BeOne's shares were up more than 1% in early trading Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","06160","BK4139","MDCO","BK4526"],"gpt_icon":0},{"id":"2538614404","title":"BeOne Medicines Ltd. Transitions to Swiss Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2538614404","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538614404?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:11","pubTimestamp":1748351502,"startTime":"0","endTime":"0","summary":"BeiGene Ltd ( ($HK:6160) ) has issued an update. BeOne Medicines Ltd., formerly known as BeiGene, Ltd., has announced its official continuation as ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-ltd-transitions-to-swiss-corporation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-ltd-transitions-to-swiss-corporation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2538677466","title":"TYK Medicines' VP Steps Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2538677466","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538677466?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:14","pubTimestamp":1748348051,"startTime":"0","endTime":"0","summary":"Jiang Mingyu resigned as TYK Medicines'  vice president among other roles effective June 13 to devote more time to other business engagements, a Tuesday Hong Kong bourse filing said.Jiang will also be re-designated from an executive director to a non-executive director of the pharmaceutical company effective the same day.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","02410"],"gpt_icon":0},{"id":"2538463262","title":"Press Release: Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2538463262","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538463262?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:31","pubTimestamp":1748345460,"startTime":"0","endTime":"0","summary":"Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy. Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors. \"This financing will enable Lexeo to build on its leadership in cardiac genetic medicines as we continue to advance our clinical stage pipeline, \" said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. \"With the support of an exceptional group of new and existing long-term investors, we believe we remain well-positioned to accelerate development of our programs and drive innovation with next-generation therapies that could redefine the treatment paradigm for devastating cardiovascular conditions.\". Lexeo intends to use net proceeds from the private placement to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes. The proceeds from this private","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LXEO","BK4082","FA","BK4130","BK4588","CSII","BK4215","MDCO","EQR","BK4535","BK4139","BK4585"],"gpt_icon":0},{"id":"2538549564","title":"TYK Medicines Announces Management Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2538549564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538549564?lang=en_us&edition=fundamental","pubTime":"2025-05-27 17:39","pubTimestamp":1748338779,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. Class H ( ($HK:2410) ) has provided an update. TYK Medicines, Inc announced the resignation of Dr. Jiang Mingyu from his roles ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-announces-management-restructuring?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-announces-management-restructuring?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2537713412","title":"Viatris' HIV-1 Generic Medicine Gets Backing From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2537713412","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537713412?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:30","pubTimestamp":1748007027,"startTime":"0","endTime":"0","summary":"The European Medicines Agency's Committee for Medicinal Products for Human Use said Friday it's recommending a marketing authorization for Viatris' (VTRS) emtricitabine/tenofovir alafenamide to treat ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VTRS","BK4585","MDCO","BK4583","LU2087621335.USD","BK4588","LU1839511570.USD","BK4007"],"gpt_icon":0},{"id":"2537312761","title":"Autolus Therapeutics' Leukemia Therapy Gets Backing From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2537312761","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537312761?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:11","pubTimestamp":1748005892,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics  said Friday that its obecabtagene autoleucel therapy has been recommended for European Commission approval by the European Medicines Agency's Committee for Medicinal Products for Human Use for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.The commission is expected to make a decision on the conditional marketing authorization application for the therapy within two months, with the decision applying to all EU member states, Iceland, Norway, and Liechtenstein, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","MDCO","BK4007","AUTL","LENZ","BK4139"],"gpt_icon":0},{"id":"2537494642","title":"Press Release: Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2537494642","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537494642?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:30","pubTimestamp":1747917000,"startTime":"0","endTime":"0","summary":"\"We are grateful for the continued support of the CIRM as we continue to rapidly enroll into our SENTI-202 clinical trial. We are committed to advancing this important program forward and based on the recently presented positive preliminary results, we are becoming more confident in its potential to provide a much-needed treatment option for patients, \" commented Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences.SENTI-202 is the Company's first-in-class off-the-shelf Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, such as AML and myelodysplastic syndrome , while sparing healthy bone marrow cells. SENTI-202 is currently being evaluated in a Phase 1 clinical trial .","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","MDCO","SNTI"],"gpt_icon":0},{"id":"2536683922","title":"TYK Medicines Included in Hang Seng Biotech Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2536683922","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536683922?lang=en_us&edition=fundamental","pubTime":"2025-05-19 18:44","pubTimestamp":1747651499,"startTime":"0","endTime":"0","summary":"TYK Medicines' (HKG:2410) H shares were selected for inclusion in the Hang Seng Biotech Index effective June 9, a Monday Hong Kong bourse filing said.The Hang Seng Biotech Index aims to reflect the overall performance of Hong Kong listed biotech companies.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","BK1161","02410"],"gpt_icon":0},{"id":"2536554855","title":"TYK Medicines Joins Hang Seng Biotech Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2536554855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536554855?lang=en_us&edition=fundamental","pubTime":"2025-05-19 08:08","pubTimestamp":1747613311,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. Class H ( ($HK:2410) ) has provided an announcement. TYK Medicines, Inc has announced that its H shares will be included in the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-joins-hang-seng-biotech-index?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-joins-hang-seng-biotech-index?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":153,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCO\",params:#limit:5,,,undefined,":[{"date":"2019-10-30","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"defaultRemindTime":1572422400000,"name":null,"time":"Pre-Market","dateTimestamp":1572408000000,"actualEps":null},{"date":"2019-07-24","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.66,"defaultRemindTime":1563955200000,"name":null,"time":"Pre-Market","dateTimestamp":1563940800000,"actualEps":-0.67},{"market":"US","date":"2019-04-25","symbol":"MDCO","fiscalQuarterEnding":"2019/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1556164800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2019-02-27","symbol":"MDCO","fiscalQuarterEnding":"2018/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2018-11-08","symbol":"MDCO","fiscalQuarterEnding":"2018/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCO\",market:\"US\",delay:false,,,undefined,":{}}}